SHARE
COPY LINK

MONSANTO

French police to probe alleged Monsanto lists on opinion-makers

France has opened a preliminary enquiry into allegations that US pesticides maker Monsanto had information illegally collected on the views and pliability of hundreds of high-profile figures and media outlets.

French police to probe alleged Monsanto lists on opinion-makers
Activists from the 'Attac' protest group scale the offices of Bayer -which recently acquired Monsanto- in La Garenne Colombes near the financial district of La Defence on the outskirts of Paris. Photo
Paris judicial police will carry out the probe following a complaint by the daily Le Monde and one of its journalists, whose names appear on the list, the Paris prosecutor's office said.
 
Two anti-pesticide NGOs — Foodwatch and Generations Futures — are also preparing to lodge legal complaints over the alleged lists.
 
The investigators will look into the possible “collection of personal information by fraudulent, unfair or illicit means”.
   
US giant Monsanto allegedly had public relations agency FleishmanHillard draw up the files on the opinions of the targeted people and media bodies on the controversial weedkiller glyphosate and on genetically modified crops as 
well as their propensity to be influenced in their opinions.
 
 
Figuring on the list are politicians, scientists and journalists — including four from AFP (Agence France-Presse). Information was collected on their views on pesticides and on Monsanto as well as their leisure pursuits, addresses and phone numbers, according to the France 2 public television channel.
   
Some of the names were listed under categories such as “priority targets” and “potential allies to recruit”, according to reports.
   
France's former environment minister Segolene Royal, whose name was said to appear on the lists, said the allegation “says a lot about the methods of lobbyists… they carry out spying, infiltration, seek to influence, sometimes financially I imagine”, adding that other companies are likely to indulge in similar practices.
   
A spokesman for FleishmanHillard told AFP: “FleishmanHillard and our staff are committed to compliance with applicable laws and we are committed to the highest standards of ethical conduct. 
   
“We continue to take that responsibility very seriously and will carefully examine the questions raised by certain media outlets about the lists of stakeholders that included publicly available information.”
   
Glyphosate developer Monsanto was convicted in the United States in 2018 and 2019 of not taking necessary steps to warn of the potential risks of Roundup — their weedkiller containing the chemical, which two California juries found caused cancer in two users.
   
German pharmaceutical firm Bayer, which bought Monsanto last year, announced last month that over 13,000 lawsuits related to the weedkiller have been launched in the US. 

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

MONSANTO

Bayer shareholders vote against board over Monsanto deal

Bayer chief executive Werner Baumann was dealt a blow on Friday at the German chemical giant's annual general meeting, amid tensions over last year's decision to buy US seeds and pesticides maker Monsanto, as disgruntled shareholders voted against management.

Bayer shareholders vote against board over Monsanto deal
Werner Baumann, chief executive of Bayer, speaks to shareholders on Friday. Photo: Guido Kirchner/dpa
At the AGM in Bonn, 55.5 percent voted against the management board, led by embattled CEO Werner Baumann, with just 44.5 percent of shareholders in favour – a huge drop down from 97 percent support last year.
   
The result is a slap in the face for Baumann and his management team, Although the vote carries no direct consequences, it is a clear statement by disgruntled shareholders.
   
Around 500 protesters gathered outside the Bonn conference centre with placards mocking Bayer's corporate motto “science for a better life” or calling to “stop glyphosate”, the Monsanto-made herbicide at the centre of the group's woes.
   
Inside, investors were fuming. “Bayer has choked on Monsanto,” said Ingo Speich of Deka bank. “The company risks being taken over and dismantled.”  Mark Tuemmler of investors' federation DSW said 2018 was “a nightmare for shareholders”.
 
'A scandal'
 
Bayer's share price fell last year by around 40 percent following its $63 billion takeover of Monsanto in June — the biggest in German history. At 57 billion euros, its market capitalisation is little higher than the price it paid to acquire Monsanto in the first place. “A scandal,” Tuemmler said.
   
Opening the meeting, Baumann acknowledged that some 13,400 US lawsuits relating to glyphosate and initial unfavourable judgements against Bayer “are placing a heavy burden on our company and worrying many people”.
   
Last year's share price plunge was driven by the first of two jury rulings so far that have awarded plaintiffs — cancer patients who had been exposed to glyphosate over long periods — $80 million each.
   
Baumann complained that such decisions had been based on a 2015 finding by World Health Organization arm IARC that glyphosate “probably” causes cancer.
 
“We remain convinced of the safety of glyphosate,” the CEO said, recalling regulators worldwide found no new evidence that the pesticide causes cancer in reviews prompted by the IARC judgement.
   
In the two cases already heard, “we remain optimistic that the next higher courts will reach different verdicts,” the CEO added, calling for “decisions based on scientific analysis — and not on emotions”.
 
READ ALSO: 
 
The business case for the merger remained as strong as ever, he assured investors, with the merged companies now operating “leading businesses in chemical and biological crop protection, in conventional and biotech seed, and also in digital farming”.
   
And he reiterated the group's targets — including its pharmaceutical and over-the-counter medicines units — to increase sales four percent, to 46 billion euros ($51 billion) in 2019, with an operating profit before special items of 12.2 billion euros.
   
Current market reactions were “exaggerated” and did not reflect Bayer's “true value”, he said.
   
By around 3:00 pm (1300 GMT), Bayer had gained around one percent on the Frankfurt stock market to trade at 61.63 euros, outperforming the DAX index of blue-chip shares.
SHOW COMMENTS